Stocktoria
CSL Limited CSL.AX
AU · Australian Securities Exchange · XASX · stock · Healthcare · website
CSL Limited financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $15.4B | $14.7B | $13.2B | $10.5B |
| Gross profit | $8.0B | $7.6B | $6.7B | $5.7B |
| R&D expense | $1.4B | $1.4B | $1.2B | $1.2B |
| SG&A expense | $2.6B | $2.4B | $2.5B | $1.6B |
| Operating income | $3.0B | $2.8B | $2.1B | $2.3B |
| Interest expense | $393.0M | $420.0M | $408.0M | $142.8M |
| Income tax | $588.0M | $661.0M | $419.0M | $524.9M |
| Net income | $3.0B | $2.6B | $2.2B | $2.3B |
| EPS (diluted) | $6.17 | $5.45 | $4.53 | $4.80 |
| Cash & equivalents | $2.2B | $1.7B | $1.5B | $10.4B |
| Inventory | $6.5B | $6.0B | $5.5B | $4.3B |
| Total assets | $39.4B | $38.0B | $36.2B | $28.3B |
| Total liabilities | $18.0B | $18.6B | $18.4B | $13.8B |
| Shareholders' equity | $19.3B | $17.4B | $15.8B | $14.6B |
Growth · year-over-year · Revenue CAGR 13.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +5.0% | +11.5% | +25.5% | — |
| Net income growth | +13.6% | +20.4% | -2.7% | — |
| EPS growth | +13.2% | +20.3% | -5.6% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · AU · as of 2025-06-30. Figures in AUD; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.